Cardiovascular Systems Inc

Cardiovascular Systems — Q2 FY2020 Earnings Presentation

8 slides from Cardiovascular Systems's earnings presentation, Feb 5, 2020

  1. Slide 1: Q2 FY20 Earnings Call February 5, 2020

    Q2 FY20 Earnings Call February 5, 2020

  2. Slide 2: Safe Harbor: Forward Looking Statements

    Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem

  3. Slide 3: Q2 Worldwide Revenues of $68.3 Million

    Q2 Worldwide Revenues of $68.3 Million 13.5% Increase in Revenue ($ in millions) Revenues US Coronary grew 22% Drivers US Peripheral grew 9% 14% unit growth Launch of full line of Drivers US support products 12% unit growth Peripheral, US Coronary, 21% OBL revenue growth $47.5 $18.5 4% hospital reve

  4. Slide 4: Financial Results

    Q2 FY20 Financial Results ($ in millions) Worldwide Peripheral Revenue Growth Worldwide Coronary Revenue Growth $48.3 $47.6 $45.5 $20.0 $20.8 $44.2 $45.2 $19.0 $18.2 8% $16.0 30% growth growth in Q2 in Q2 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 Gross Margin Ca

  5. Slide 5: Highlights

    Q2 FY20 Highlights Financial Operational - Peripheral Operational – Coronary Other Revenue Growth +13.5% vs. LY • Strong case support drove • Growing adoption of coronary • Sold >22,500 OAS units strength in hospitals and office toolkit featuring OAS with • Certified 66 international Gross Margin 79

  6. Slide 6: Key Events & Milestones

    Key Events & Milestones FY19A FY20E FY21E Sold 80,650 OAS WIRION acquisition • Hemodynamic support - First in Human International revenue = $7.9M LIBERTY 360 3-Year Data • International revenue = $15-$17.5M Launched OAS in SE Asia, Europe • Launch OAS in up to 10 new countries • Launch OAS in Canada

  7. Slide 7: FY20 Guidance (as of 2-5-20)

    FY20 Guidance (as of 2-5-20) For fiscal 2020 ending June 30, 2020, CSI anticipates: • Revenue of $280 million to $283 million, representing 13% to 14% growth compared with fiscal 2019; • Gross profit margin of 79% to 80%; • Net loss of approximately 2% of revenues, including approximately $1 million

  8. Slide 8: Investor Contact

    Investor Contact: Jack Nielsen 651-202-4919 j.nielsen@csi360.com CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2019 Cardiovascular Systems, Inc. CSII OrbusNeich®, Teleport® and Sapphire® are trademarks

Cardiovascular Systems — Q2 FY2020 Earnings Presentation on 6ix